18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 6, 2012, Pages 1030-1036

  Ciarmiello, Andrea ^a   Giovacchini, Giampiero ^a   Orobello, Sara ^b   Bruselli, Laura ^a   Elifani, Francesca ^b   Squitieri, Ferdinando ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

18F FDG PET scan; Age at onset prediction; Caudate glucose metabolism; Phenoconversion

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; GLUCOSE;

ADULT; ARTICLE; CAG REPEAT; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; GENE STRUCTURE; GENETIC RISK; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MUTATION SIZE; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRE HUNTINGTON CHOREA; PREDICTION; RATING SCALE; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE REPEAT; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGE OF ONSET; BIOLOGICAL TRANSPORT; CAUDATE NUCLEUS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REPETITIVE SEQUENCES, NUCLEIC ACID; YOUNG ADULT;

EID: 84862658038     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2114-z     Document Type: Article

References (37)

1. ST Grafton JC Mazziotta JJ Pahl P St George-Hyslop JL Haines J Gusella, et al. 1992 Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease Arch Neurol 49 1161 1167 1444883 10.1001/archneur.1992.00530350075022 1:STN:280:DyaK3s%2FnsVGiuw%3D%3D
2. T Kuwert HW Lange H Boecker H Titz H Herzog A Aulich, et al. 1993 Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease J Neurol 241 31 36 8138819 10.1007/BF00870669 1:STN:280: DyaK2c7os1yhuw%3D%3D
3. A Antonini KL Leenders R Spiegel D Meier P Vontobel M Weigell-Weber, et al. 1996 Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease Brain 119 Pt 6 2085 2095 9010012 10.1093/brain/119.6.2085
4. A Feigin M Fukuda V Dhawan S Przedborski V Jackson-Lewis MJ Mentis, et al. 2001 Metabolic correlates of levodopa response in Parkinson's disease Neurology 57 2083 2088 11739830 1:CAS:528:DC%2BD38XivVyjsQ%3D%3D
5. A Ciarmiello M Cannella S Lastoria M Simonelli L Frati DC Rubinsztein, et al. 2006 Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease J Nucl Med 47 215 222 16455626 1:CAS:528:DC%2BD28Xhslantr8%3D
6. RR Brinkman MM Mezei J Theilmann E Almqvist MR Hayden 1997 The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size Am J Hum Genet 60 1202 1210 9150168 1:CAS:528:DyaK2sXjtlOqs70%3D
7. F Squitieri G Sabbadini P Mandich C Gellera E Di Maria E Bellone, et al. 2000 Family and molecular data for a fine analysis of age at onset in Huntington disease Am J Med Genet 95 366 373 11186892 10.1002/1096-8628(20001211)95: 4<366::AID-AJMG13>3.0.CO;2-2 1:STN:280:DC%2BD3M7it1Grtg%3D%3D
8. DR Langbehn RR Brinkman D Falush JS Paulsen MR Hayden 2004 A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length Clin Genet 65 267 277 10.1111/j.1399-0004.2004.00241.x 15025718 10.1111/j.1399-0004.2004.00241.x 1:STN:280:DC%2BD2c7msVertg%3D%3D
9. DC Rubinsztein J Leggo R Coles E Almqvist V Biancalana JJ Cassiman, et al. 1996 Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats Am J Hum Genet 59 16 22 8659522 1:CAS:528:DyaK28XksFSisLg%3D
10. NS Wexler J Lorimer J Porter F Gomez C Moskowitz E Shackell, et al. 2004 Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset Proc Natl Acad Sci U S A 101 3498 3503 10.1073/pnas.0308679101 14993615 10.1073/pnas.0308679101 1:CAS:528: DC%2BD2cXisFWmsbg%3D
11. M Esmaeilzadeh A Ciarmiello F Squitieri 2011 Seeking brain biomarkers for preventive therapy in Huntington disease CNS Neurosci Ther 17 368 386 10.1111/j.1755-5949.2010.00157.x 20553306 10.1111/j.1755-5949.2010.00157.x 1:CAS:528:DC%2BC3MXhtlOntL%2FM
12. JB Penney Jr AB Young I Shoulson S Starosta-Rubenstein SR Snodgrass J Sanchez-Ramos, et al. 1990 Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals Mov Disord 5 93 99 2139171 10.1002/mds.870050202
13. N Lynoe M Sandlund G Dahlqvist L Jacobsson 1991 Informed consent: study of quality of information given to participants in a clinical trial BMJ 303 610 613 1932901 10.1136/bmj.303.6803.610 1:STN:280:DyaK38%2Fjtlehtg%3D%3D
14. Huntington Study Group 1996 Unified Huntington's disease rating scale: reliability and consistency Mov Disord 11 136 142 10.1002/mds.870110204
15. F Squitieri C Gellera M Cannella C Mariotti G Cislaghi DC Rubinsztein, et al. 2003 Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course Brain 126 946 955 12615650 10.1093/brain/awg077
16. B Alfano A Brunetti EM Covelli M Quarantelli MR Panico A Ciarmiello, et al. 1997 Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach Magn Reson Med 37 84 93 8978636 10.1002/mrm.1910370113 1:STN:280:DyaK2s7jtlaguw%3D%3D
17. M Quarantelli K Berkouk A Prinster B Landeau C Svarer L Balkay, et al. 2004 Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction J Nucl Med 45 192 201 14960635
18. HW Muller-Gartner JM Links JL Prince RN Bryan E McVeigh JP Leal, et al. 1992 Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects J Cereb Blood Flow Metab 12 571 583 10.1038/jcbfm.1992.81 1618936 10.1038/jcbfm.1992.81 1:STN:280:DyaK38zhslajug%3D%3D
19. OG Rousset Y Ma AC Evans 1998 Correction for partial volume effects in PET: principle and validation J Nucl Med 39 904 911 9591599 1:STN:280: DyaK1c3lt1aksQ%3D%3D
20. S Minoshima KA Frey NL Foster DE Kuhl 1995 Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis J Comput Assist Tomogr 19 541 547 7622680 10.1097/00004728- 199507000-00006 1:STN:280:DyaK2MzkvVehsA%3D%3D
21. AM Brickman MS Buchsbaum L Shihabuddin EA Hazlett JC Borod RC Mohs 2003 Striatal size, glucose metabolic rate, and verbal learning in normal aging Brain Res Cogn Brain Res 17 106 116 12763197 10.1016/S0926-6410(03)00085-5 1:CAS:528:DC%2BD3sXjvFags70%3D
22. MC Petit-Taboue B Landeau JF Desson B Desgranges JC Baron 1998 Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping Neuroimage 7 176 184 10.1006/nimg.1997.0318 9597659 10.1006/nimg.1997.0318 1:STN:280:DyaK1c3lvF2ntQ%3D%3D
23. JA Hanley BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 29 36 7063747 1:STN:280:DyaL387ltFyksQ%3D%3D
24. SJ Tabrizi DR Langbehn BR Leavitt RA Roos A Durr D Craufurd, et al. 2009 Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol 8 791 801 10.1016/S1474-4422(09)70170-X 19646924 10.1016/S1474-4422(09) 70170-X
25. A Yamamoto JJ Lucas R Hen 2000 Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 57 66 10.1016/S0092-8674(00)80623-6 10778856 10.1016/S0092-8674(00)80623-6 1:CAS:528:DC%2BD3cXisVaitbk%3D
26. EH Aylward BF Sparks KM Field V Yallapragada BD Shpritz A Rosenblatt, et al. 2004 Onset and rate of striatal atrophy in preclinical Huntington disease Neurology 63 66 72 15249612 1:STN:280:DC%2BD2czks1Kkug%3D%3D
27. HH Ruocco L Bonilha LM Li I Lopes-Cendes F Cendes 2008 Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat J Neurol Neurosurg Psychiatry 79 130 135 10.1136/jnnp.2007.116244 17615168 10.1136/jnnp.2007.116244 1:STN:280: DC%2BD1c%2FkslWrug%3D%3D
28. F Squitieri M Cannella M Simonelli J Sassone T Martino E Venditti, et al. 2009 Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease CNS Neurosci Ther 15 1 11 10.1111/j.1755-5949.2008.00068.x 19228174 10.1111/j.1755-5949.2008.00068.x
29. WJ Powers TO Videen J Markham L McGee-Minnich JV Antenor-Dorsey T Hershey T, et al. 2007 Selective defect of in vivo glycolysis in early Huntington's disease striatum Proc Natl Acad Sci U S A 104 8 2945 2949 10.1083/jcb.200508072 17299049 10.1073/pnas.0609833104 1:CAS:528:DC%2BD2sXisVSmsLk%3D
30. JY Shin ZH Fang ZX Yu CE Wang SH Li XJ Li 2005 Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity J Cell Biol 171 1001 1012 10.1083/jcb.200508072 16365166 10.1083/jcb.200508072 1:CAS:528:DC%2BD2MXhtlequ7fF
31. H Li SH Li ZX Yu P Shelbourne XJ Li 2001 Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice J Neurosci 21 8473 8481 11606636 1:CAS:528:DC%2BD3MXnvVeqsLk%3D
32. LR Gauthier BC Charrin M Borrell-Pages JP Dompierre H Rangone FP Cordelieres, et al. 2004 Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules Cell 118 127 138 10.1016/j.cell.2004.06.018 15242649 10.1016/j.cell.2004.06.018 1:CAS:528:DC%2BD2cXlvFejtbc%3D
33. G Battaglia M Cannella B Riozzi S Orobello ML Maat-Schieman E Aronica, et al. 2011 Early defect of transforming growth factor beta1 formation in Huntington's disease J Cell Mol Med 15 555 571 10.1111/j.1582-4934.2010.01011.x 20082658 10.1111/j.1582-4934.2010.01011.x 1:CAS:528:DC%2BC3MXmslWmu74%3D
34. R Gonitel H Moffitt K Sathasivam B Woodman PJ Detloff RL Faull, et al. 2008 DNA instability in postmitotic neurons Proc Natl Acad Sci U S A 105 3467 3472 10.1073/pnas.0800048105 18299573 10.1073/pnas.0800048105 1:CAS:528:DC%2BD1cXjtlanu7Y%3D
35. M Cannella V Maglione T Martino G Ragona L Frati GM Li, et al. 2009 DNA instability in replicating Huntington's disease lymphoblasts BMC Med Genet 10 11 10.1186/1471-2350-10-11 19210789 10.1186/1471-2350-10-11
36. M Swami AE Hendricks T Gillis T Massood J Mysore RH Myers, et al. 2009 Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset Hum Mol Genet 18 3039 3047 10.1093/hmg/ddp242 19465745 10.1093/hmg/ddp242 1:CAS:528:DC%2BD1MXptVamsbo%3D
37. JL Li MR Hayden EW Almqvist RR Brinkman A Durr C Dode, et al. 2003 A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study Am J Hum Genet 73 682 687 10.1086/378133 12900792 10.1086/378133 1:CAS:528:DC%2BD3sXnt1WqsLw%3D